Showing Results for: “diabetes”

Study Results Signal Paradigm Shift in Diabetes Care for Patients with Difficult-to-Control Type 2 Diabetes New findings from the CATALYST study show that the use of mifepristone resulted in improved blood glucose (blood sugar) control and weight reduction in patients with difficult-to-control type 2 diabetes and hypercortisolism. The results of the largest prospective trial of its kind were presented as a late-breaking symposium at the 85th Scientific Sessions of the American Diabetes Association® (ADA) in Chicago, and simultaneously published in Diabetes Care®. Among patients with type 2

Today, the American Diabetes Association® (ADA) and Genentech, a member of the Roche Group, announced a program to increase equitable access to eye health care in the Washington, DC metropolitan area. The program, an extension of the Health Equity Now® initiative, will focus on identifying and removing barriers to care facing Black and Hispanic/Latino communities in the DC region. Diabetes-related eye disease affects nearly 8 million Americans and is the leading cause of vision loss in people 18–64 years old. Black, Native American/Alaska Native, Hispanic/Latino, and older adults living with

The American Diabetes Association® (ADA) applauds Illinois Governor J.B. Pritzker for signing legislation (Senate Bill 3414) allowing a broader population of Illinois’ Medicaid beneficiaries to be eligible for a continuous glucose monitor (CGM), closing a significant health equity gap in access to care for people with diabetes who are insulin dependent. CGMs continually monitor blood glucose (blood sugar), giving real-time updates through a device that is attached to a person’s body. People with diabetes who use a CGM have fewer instances of hypoglycemia (low blood glucose) and can achieve a

This week, California became the 29th state to approve legislation capping the costs of insulin for Californians on private state-regulated health plans. The American Diabetes Association ® (ADA) applauds Governor Gavin Newsom’s decision to sign Senate Bill 40, addressing insulin affordability by limiting cost-sharing for insulin to $35 for a 30-day supply. In California, approximately 3.5 million adults have diagnosed diabetes. And while not all use insulin, those who do rely on it to survive. “For far too long, many Americans with diabetes have made the difficult decision to ration this

In response to recent news of the executive order calling for the dismantling of the U.S. Department of Education, the American Diabetes Association® (ADA) issues the following statement: “The ADA is extremely concerned about the adverse impact of dismantling the U.S. Department of Education upon 352,000 children and adolescents today in the U.S. living with diabetes, a disability under federal law. The ADA is concerned that these actions will diminish its ability to oversee and enforce legal protections for these children under Section 504 of the Rehabilitation Act, the Americans with

New Study Highlights Potential of CGM to Help Patients Improve Diabetes Management in Primary Care Settings A new study examining the role of continuous glucose monitoring (CGM) in the management of adults with type 2 diabetes who are not on insulin found that CGM substantially reduced hyperglycemia, resulting in a large reduction in A1C compared with a routine care control group. Researchers presented this data today as an oral abstract at the 2026 Scientific Sessions of the American Diabetes Association ® (ADA) in New Orleans. As detailed in the ADA Standards of Care, there is strong, clear

El Proyecto Tiene Como Objetivo Remover Barreras al Acceso a Cuidados de la Salud para Prevenir la Perdida de Visión El día de hoy, la Asociación Americana de la Diabetes (ADA) y Genentech, miembro del Grupo Roche, anunciaron una nueva colaboración como parte del trabajo en el marco de la iniciativa de la ADA “ Health Equity Now” para hacer frente a la falta de acceso a exámenes médicos y tratamientos para enfermedades oculares que afectan a las personas con diabetes. La diabetes es la principal causa de pérdida de visión en personas entre 18 y 64 años, y las personas afroamericanas, indígenas

American Diabetes Association ® partners with Abbott to donate 25,000 CGM sensors to hospitals across the country Recently, the Food and Drug Administration (FDA) issued guidance to expand the availability and capability of non-invasive remote monitoring devices during the COVID-19 pandemic. This change was made in an effort to improve the ability of health care providers to monitor their patients while reducing their exposure to the novel coronavirus. The new policy will apply to non-invasive patient monitoring technology, including continuous glucose monitors (CGM), and expands their

The American Diabetes Association ® (ADA) recognizes North Carolina’s action to preserve Medicaid coverage for U.S. Food and Drug Administration (FDA)-approved weight-management medications, safeguarding access to evidence-based care for people living with diabetes, obesity, or both. “We appreciate North Carolina’s decision to continue coverage for obesity medication,” said Monica Billger, the ADA’s director of state government affairs. “This action helps ensure people who rely on Medicaid can continue accessing the care and treatment they need to manage their health.” Nearly 35% of the state

Today, the American Diabetes Association® (ADA) applauded Kentucky Governor Andy Beshear for signing legislation that will cap insulin co-pays at $30 per month, regardless of the quantity or type of insulin needed to fill the insured patient's prescription. Governor Beshear and bill sponsor Representative Danny Bentley provided expert leadership on this important legislation to reduce the burden of insulin costs for people living with diabetes. Kentucky joins 14 other states as well as the District of Columbia that have enacted insulin copay caps to reduce costs of this life-saving drug.